Chemical Biology & Drug Design

Chemical Biology & Drug Design is a monthly peer-reviewed journal that covers the multidisciplinary ground where chemistry, biology and computation meet in the search for new medicines.《Chemical Biology & Drug Design》是一份月刊同行评审期刊，覆盖化学、生物学与计算在寻找新药时相遇的跨学科领域。

It is published by John Wiley & Sons and grew out of the medicinal chemistry list of Blackwell, appearing under its present title in 2006.该刊由约翰威立出版，脱胎于布莱克韦尔的药物化学刊物，2006 年启用现名。

In the 2025 edition of the journal citation report it holds an impact factor of 3.3, and it stands in the third quartile of biochemistry and molecular biology.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在生物化学与分子生物学类目列第三区。

Scope

• The journal is devoted to chemical biology and to drug design, and it treats the two as one connected field rather than as separate specialties.该刊致力于化学生物学与药物设计，把二者当作一个相连的领域，而不是彼此分离的专业。

• Medicinal chemistry is a core subject, and work on how a compound is built and how it behaves in the body is admitted.药物化学是核心选题，关于化合物如何构建、在体内如何表现的工作受到收载。

• Drug design is pursued at the level of the molecule, and the journal carries work on how a target is chosen and how a candidate is shaped to fit it.药物设计在分子层面展开，该刊刊载关于如何选定靶点、如何塑造候选分子以适配它的工作。

• Chemical biology is treated in its own right, and the journal takes work that uses chemical tools to ask a question about a living system.化学生物学作为独立方向得到处理，该刊收载运用化学工具对生命系统提出问题的研究。

• Computational and structural methods are part of the remit, and the journal admits work on modelling and on the determination of molecular structure.计算与结构方法属于收稿范围，该刊收载分子建模与结构测定方面的工作。

• Protein and peptide science is covered, and work on how a chain folds and how it is recognised by a partner is admitted.蛋白质与多肽科学得到覆盖，关于链如何折叠、如何被搭档识别的工作受到收载。

• Nucleic acid chemistry appears among the subjects, and the journal carries work on modified bases and on the recognition of a sequence.核酸化学列于选题之中，该刊刊载修饰碱基与序列识别方面的工作。

• Enzymes and their inhibitors are treated, and the journal takes work on how an inhibitor is found and how it is made selective.酶及其抑制剂得到处理，该刊收载关于抑制剂如何被发现、如何被做得具有选择性的工作。

• Antibacterials and the problem of resistance are named, and the journal admits work on compounds that act against a resistant strain.抗菌药与耐药问题被点名，该刊收载作用于耐药菌株的化合物方面的工作。

• Oncology is part of the remit, and work on molecules that act against a tumour and on how they are designed appears in its pages.肿瘤学属于收稿范围，关于作用于肿瘤的分子及其设计方式的工作见诸其页。

• Pharmacokinetics and drug metabolism are weighed, and the journal asks how a compound is taken up, changed and cleared.药代动力学与药物代谢受到权衡，该刊追问化合物如何被摄取、转化与清除。

• Fragment based and structure guided approaches are treated, and the journal carries work that grows a small binder into a lead.片段法与结构导向法得到处理，该刊刊载把小型结合体培植为先导化合物的研究。

• Chemical synthesis and methodology are admitted, and the journal takes work on a new route or a new reagent that serves drug discovery.化学合成与方法学受到收载，该刊收载服务于药物发现的新路线或新试剂方面的工作。

History

• The title appeared in 2006, when the publisher's peptide and protein journals were brought together under a name that names both chemistry and drug design.该刊于 2006 年出现，出版方把其肽与蛋白质刊物归拢到一个兼指化学与药物设计的题名之下。

• It was issued at first by Blackwell, and the list passed to John Wiley & Sons when the two houses were combined.该刊最初由布莱克韦尔发行，两家合并后刊物名录转入约翰威立名下。

• The journal kept the same pair of numbers through the change of owner, and the print and electronic editions share one string of digits.该刊在所有人变更的全程保留同一对刊号，印本与电子版共用一串数字。

• David Selwood of University College London served as editor-in-chief, and the journal's peer review list records his name in that office.伦敦大学学院的（David Selwood）曾出任主编，该刊的评审名录记录了他担任此职。

• The office later passed to Roberta Melander, and the masthead now names her alone as editor-in-chief.主编之职后来传至（Roberta Melander），现行版权页仅列她为主编。

• Six issues are gathered into a year in the present arrangement, and volumes 105 to 107 ran through 2025.按现行安排该刊每年汇集六期，105 至 107 卷延续至 2025 年。

• The impact figure has hovered near three for several editions, standing at 2.817 for 2021 and reaching 3.3 in the 2025 edition.影响因子连续几版徘徊在 3 附近，2021 年为 2.817，2025 年版为 3.3。

• A note of concern and a retraction have been issued under the journal's name, and the publisher records the editor's agreement to each.该刊名下曾刊出关注声明与撤稿声明，出版方记录了主编对每一份的同意。

• The journal is indexed in the science citation index expanded, and it is carried in MEDLINE and in PubMed.该刊被科学引文索引扩展版收录，并被 MEDLINE 与 PubMed 收录。

• It is also abstracted in chemical abstracts and in the international pharmaceutical abstracts, and its content is preserved in the usual archives.该刊亦被化学文摘与国际药学文摘收录，其内容保存在惯常的档案之中。

• Special issues are assembled around themes, and the journal has gathered papers on such subjects as antimicrobial discovery.该刊围绕主题编成专刊，曾汇集抗微生物药物发现一类题目的论文。

Editors

• Roberta Melander, a research associate professor at the University of Notre Dame, is editor-in-chief, and her own work concerns small molecules that govern bacterial communication.（Roberta Melander）是圣母大学的研究副教授，担任主编，其本人研究涉及调控细菌通讯的小分子。

• A group of handling editors works under her, and the journal lists names from China, Britain, Japan, South Africa and Brazil.其下有一组责任编辑，该刊列出的人员来自中国、英国、日本、南非与巴西。

• An editorial advisory board of established scientists advises on direction, and its members come from universities across Europe, Asia and North America.一个由资深科学家组成的编辑顾问委员会为方向提供建议，其成员来自欧洲、亚洲与北美的多所大学。

• A journal office at the publisher handles manuscripts, and an editorial assistant is named as the point of contact for authors.出版方所设的期刊办公室处理稿件，一位编辑助理被列为作者的联络人。

• Manuscripts are submitted through the publisher's system, and those that do not meet the instructions are returned before review.稿件通过出版方的系统投递，不符合说明的会在评审之前退回。

• Each paper is sent to independent referees, and the journal reports a submission-to-first-decision time of about five days.每篇论文送交独立审稿人，该刊报告从投稿到首次决定约为五天。

• The journal states the classes of manuscript it takes, and it sets out the length and structure each class should follow.该刊写明所收稿件的类别，并列出各类别应遵循的篇幅与结构。

• Ethical requirements are set out in full, and authors must declare any competing interest.伦理要求有完整说明，作者必须声明任何利益冲突。

• Figure preparation is given its own guidance, and the journal asks that images be free of improper manipulation.图像制作另有专门指引，该刊要求图像不含不当处理。

• Data sharing is encouraged, and the journal points to the publisher's policy that governs it.该刊鼓励数据共享，并指明出版方约束此事的政策。

• Accepted papers may be published under an open licence on payment of a charge, or through the subscription route.被录用的论文可以在缴纳费用后以开放许可发表，也可以走订阅路径。

• The journal is read by medicinal chemists and by structural biologists, by computational chemists and by pharmacologists, and it writes for all of them.该刊的读者既有药物化学家与结构生物学家，也有计算化学家与药理学家，它为这几类人写作。

• Studies that report a negative result or an unexpected property are taken, since a compound that fails is worth recording.报告阴性结果或意外性质的研究也在收载之列，因为失败的化合物同样值得记录。

• The journal keeps its reviews and its original reports distinct, and a reader can tell from the rubric which is which.该刊把综述与原始报告区分开来，读者可从栏目看出何者为何者。

• Work at the interface between chemistry and medicine is given particular weight, and the journal asks how a discovery is carried toward a clinic.化学与医学交界处的工作尤受重视，该刊追问一项发现如何被带向临床。

• Where a structure is central to the claim, the journal asks that the data behind it be made available to readers.若结构对论断至关重要，该刊要求其背后的数据可供读者获取。

• The journal follows the publisher in matters of research integrity, and an editor is named in the record of any correction or withdrawal.该刊在研究诚信事务上遵循出版方的做法，任何更正或撤稿的记录中都列有主编之名。